Nephrology
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
Seon Ha Baek, Hyunsuk Kim, Jeonghwan Lee, Dong Ki Kim, Kook-Hwan Oh, Yon Su Kim, Jin Suk Han, Tae Min Kim, Se-Hoon Lee, Kwon-Wook Joo
Korean J Intern Med. 2014;29(1):40-48. Published online January 2, 2014
Background/Aims: Sunitinib is an oral multitargeted tyrosine kinase inhibitor
used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse
effects (RAEs) of sunitinib have not been investigated. The aim of this study
was to determine the incidence and risk factors of RAEs (..
|